Advanced search

Vol 27, No 2 (2022)
Review paper
Published online: 2022-03-07

open access

View PDF Download PDF file
Page views 5981
Article views/downloads 394
Get Citation

Connect on Social Media

Connect on Social Media

Tailored treatment strategies for cancer patients during COVID-19 pandemic

Haytham Abdelkader1, Mohamed El Kassas2
DOI: 10.5603/RPOR.a2022.0024
Rep Pract Oncol Radiother 2022;27(2):318-330.

Abstract

The global pandemic of respiratory disease caused by the novel human coronavirus (SARS-CoV-2) has caused indefinite global distress, uncertainty, and disturbance. This pandemic has had direct and indirect impacts for the healthcare systems across the world, but certain subgroups of patients have been particularly affected. Among these groups are patients with cancer, who as a result of their immunosuppressed status either from the disease itself or as a consequence of treatment, are at increased risk of severe COVID-19 infection and complications. The pandemic has also led to limited resources as medical services have been primarily directed to emergency care. In this context, physicians and healthcare providers have had to balance the importance of continuing treatment of cancer patients with the risk of virus infection.    

In this review, we outline the treatment strategies for cancer patients during this pandemic, focusing on tailored treatment in this challenging situation of varying risks and benefits.

Keywords: COVID-19cancertailored treatmentchemotherapyradiation therapy

Article available in PDF format

View PDF Download PDF file

References

  1. Killerby ME, Biggs HM, Haynes A, et al. Human coronavirus circulation in the United States 2014-2017. J Clin Virol. 2018; 101: 52–56.
    CrossRefPubMed
  2. Harky A, Chiu CM, Yau TH, et al. Cancer Patient Care during COVID-19. Cancer Cell. 2020; 37(6): 749–750.
    CrossRefPubMed
  3. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020; 43(6): 452–455.
    CrossRefPubMed
  4. Rakhsha A, Azghandi S, Taghizadeh-Hesary F. COVID-19 pandemic and patients with cancer: The protocol of a Clinical Oncology center in Tehran, Iran. Rep Pract Oncol Radiother. 2020; 25(5): 765–767.
    CrossRefPubMed
  5. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335–337.
    CrossRefPubMed
  6. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021; 7(2): 220–227.
    CrossRefPubMed
  7. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8): 1023–1034.
    CrossRefPubMed
  8. Zadnik V, Mihor A, Tomsic S, et al. Impact of COVID-19 on cancer diagnosis and management in Slovenia - preliminary results. Radiol Oncol. 2020; 54(3): 329–334.
    CrossRefPubMed
  9. Celayir MF, Aygun N, Tanal M, et al. How should be the Surgical Treatment Approach during the COVID-19 Pandemic in Patients with Gastrointestinal Cancer? Sisli Etfal Hastan Tip Bul. 2020; 54(2): 136–141.
    CrossRefPubMed
  10. Liu Z, Zhang Y, Wang X, et al. Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. Indian J Surg. 2020 [Epub ahead of print]: 1–5.
    CrossRefPubMed
  11. Aygun N, Iscan Y, Ozdemir M, et al. Endocrine Surgery during the COVID-19 Pandemic: Recommendations from the Turkish Association of Endocrine Surgery. Sisli Etfal Hastan Tip Bul. 2020; 54(2): 117–131.
    CrossRefPubMed
  12. Ngaserin SHN, Koh FH, Ong BC, et al. COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient. Langenbecks Arch Surg. 2020; 405(3): 353–355.
    CrossRefPubMed
  13. Hadjittofi C, Seraj SS, Uddin A, et al. Laparoscopic vs open surgery during the COVID-19 pandemic: what are the risks? Ann R Coll Surg Engl. 2021; 103(5): 354–359.
    CrossRefPubMed
  14. Zheng MH, Boni L, Fingerhut A. Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China and Italy. Ann Surg. 2020; 272(1): e5–e6.
    CrossRefPubMed
  15. Vigneswaran Y, Prachand VN, Posner MC, et al. What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate? J Gastrointest Surg. 2020; 24(7): 1686–1691.
    CrossRefPubMed
  16. Allaix ME, Lo Secco G, Velluti F, et al. Colorectal surgery during the COVID-19 outbreak: do we need to change? Updates Surg. 2021; 73(1): 173–177.
    CrossRefPubMed
  17. Tseng LN, Berends FJ, Wittich P, et al. Port-site metastases. Impact of local tissue trauma and gas leakage. Surg Endosc. 1998; 12(12): 1377–1380.
    CrossRefPubMed
  18. Brundell SM, Tucker K, Texler M, et al. Variables in the spread of tumor cells to trocars and port sites during operative laparoscopy. Surg Endosc. 2002; 16(10): 1413–1419.
    CrossRefPubMed
  19. Liu Z, Ding Z, Guan Xu, et al. Optimizing response in surgical systems during and after COVID-19 pandemic: Lessons from China and the UK - Perspective. Int J Surg. 2020; 78: 156–159.
    CrossRefPubMed
  20. Francis N, Dort J, Cho E, et al. SAGES and EAES recommendations for minimally invasive surgery during COVID-19 pandemic. Surg Endosc. 2020; 34(6): 2327–2331.
    CrossRefPubMed
  21. Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487–497.
    CrossRefPubMed
  22. Dowsett M, Ellis MJ, Dixon JM, et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer. 2020; 6: 21.
    CrossRefPubMed
  23. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; 172(9): 577–582.
    CrossRefPubMed
  24. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020; 323(14): 1406–1407.
    CrossRefPubMed
  25. O'Leary MP, Choong KC, Thornblade LW, et al. Management Considerations for the Surgical Treatment of Colorectal Cancer During the Global Covid-19 Pandemic. Ann Surg. 2020; 272(2): e98–e9e105.
    CrossRefPubMed
  26. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335.
    CrossRefPubMed
  27. Young BE, Ong SW, Kalimuddin S, et al. Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 323(15): 1488–1494.
    CrossRefPubMed
  28. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020; 382(12): 1177–1179.
    CrossRefPubMed
  29. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infect Dis. 2006; 42(11): 1561–1569.
    CrossRefPubMed
  30. Santarpia J, Rivera D, Herrera V, et al. Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. medRxiv. .
    CrossRef
  31. Day AT, Sher DJ, Lee RC, et al. Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. Oral Oncol. 2020; 105: 104684.
    CrossRefPubMed
  32. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6): 783–791.
    CrossRefPubMed
  33. Giannakoulis VG, Papoutsi E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 2020; 6: 799–808.
    CrossRefPubMed
  34. Kuderer NM, Choueiri TK, Shah DP, et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241): 1907–1918.
    CrossRefPubMed
  35. American Society for Radiation Oncology. COVID-19 recommendations and information: COVID-19 clinical guidance. 2020. https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/Clinical-Guidance (August 3, 2020).
  36. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020; 135(21): 1829–1832.
    CrossRefPubMed
  37. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012; 13(6): 579–588.
    CrossRefPubMed
  38. Zou XC, Wang QW, Zhang JM. Comparison of 5-FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis. Clin Colorectal Cancer. 2017; 16(3): e123–e139.
    CrossRefPubMed
  39. Shereen NG, Salman D. Delivering chemotherapy at home: how much do we know? Br J Community Nurs. 2019; 24(10): 482–484.
    CrossRefPubMed
  40. American Society of Hematology. COVID-19 and hodgkin lymphoma: frequently asked questions. 2020. https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma (August 3, 2020).
  41. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020; 38(30): 3538–3546.
    CrossRefPubMed
  42. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020; 190(5): e279–e282.
    CrossRefPubMed
  43. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020; 217(6).
    CrossRefPubMed
  44. Dumoulin DW, Gietema HA, Paats MS, et al. Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. Front Oncol. 2020; 10: 577696.
    CrossRefPubMed
  45. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020; 141: 92–104.
    CrossRefPubMed
  46. Thomson DJ, Yom SS, Saeed H, et al. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. Int J Radiat Oncol Biol Phys. 2020; 108(2): 379–389.
    CrossRefPubMed
  47. Lancia A, Bonzano E, Bottero M, et al. Radiotherapy in the era of COVID-19. Expert Rev Anticancer Ther. 2020; 20(8): 625–627.
    CrossRefPubMed
  48. Malicki J, Martenka P, Dyzmann-Sroka A, et al. Impact of COVID-19 on the performance of a radiation oncology department at a major comprehensive cancer centre in Poland during the first ten weeks of the epidemic. Rep Pract Oncol Radiother. 2020; 25(5): 820–827.
    CrossRefPubMed
  49. Parashar B, Chen WC, Herman JM, et al. Disease Site-Specific Guidelines for Curative Radiation Treatment During 'Limited Surgery' and 'Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. Cureus. 2020; 12(5): e8190.
    CrossRefPubMed
  50. Chen WC, Teckie S, Somerstein G, et al. Guidelines to reduce hospitalization rates for patients receiving curative-intent radiation therapy during the COVID-19 pandemic: report from a multicenter New York area institution. Adv Radiat Oncol. 2020; 5(4): 621–627.
    CrossRef
  51. Thomson D, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020; 151: 314–321.
    CrossRefPubMed
  52. Wu JA, Rimner A, Shepherd AF, et al. Thoracic radiation therapy during COVID-19: provisional guidelines from a comprehensive cancer center within a pandemic epicenter. Adv Radiat Oncol. 2020; 5(4): 603–607.
    CrossRefPubMed
  53. Romesser PB, Wu AJ, Cercek A, et al. Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. Adv Radiat Oncol. 2020; 5(4): 687–689.
    CrossRefPubMed
  54. Spencer K, Jones C, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021; 22(3): 309–320.
    CrossRefPubMed
  55. Braunstein LZ, Gillespie EF, Hong L, et al. Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints-Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States. Adv Radiat Oncol. 2020; 5(4): 582–588.
    CrossRefPubMed
  56. Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015; 33(33): 3938–3944.
    CrossRefPubMed
  57. McCormick B. RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol. 2012; 30(15_suppl): 1004–1004.
    CrossRef
  58. Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol. 2016; 23(12): 3801–3810.
    CrossRefPubMed
  59. Haviland J, Owen J, Dewar J, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086–1094.
    CrossRefPubMed
  60. Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. FAST Trialists group. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011; 100(1): 93–100.
    CrossRefPubMed
  61. Brunt AM, Wheatley D, Yarnold J, et al. FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016; 120(1): 114–118.
    CrossRefPubMed
  62. National Comprehensive Cancer Network. Rectal Cancer. NCCN Guidelines Version 2020.
  63. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10): 1215–1223.
    CrossRefPubMed
  64. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31): 3827–3833.
    CrossRefPubMed
  65. Marijnen CAM, Peters FP, Rödel C, et al. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol. 2020; 148: 213–215.
    CrossRefPubMed
  66. Faivre-Finn C, Fenwick JD, Franks KN, et al. Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020; 32(8): 481–489.
    CrossRefPubMed
  67. Liao Z, Rivin Del Campo E, Salem A, et al. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer. 2020; 146: 230–235.
    CrossRefPubMed
  68. Manyam BV, Videtic GMM, Verdecchia K, et al. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2019; 9(2): e187–e195.
    CrossRefPubMed
  69. Ma JT, Liu Y, Sun Li, et al. Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. Int J Radiat Oncol Biol Phys. 2019; 103(4): 843–850.
    CrossRefPubMed
  70. Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys. 2011; 80(3): 692–697.
    CrossRefPubMed
  71. Asai K, Shioyama Y, Nakamura K, et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship. Int J Radiat Oncol Biol Phys. 2012; 84(3): 768–773.
    CrossRefPubMed
  72. Bongers EM, Haasbeek CJA, Lagerwaard FJ, et al. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol. 2011; 6(12): 2052–2057.
    CrossRefPubMed
  73. Prewett SL, Aslam S, Williams MV, et al. The management of lung cancer: a UK survey of oncologists. Clin Oncol (R Coll Radiol). 2012; 24(6): 402–409.
    CrossRefPubMed
  74. Hamdy FC, Donovan JL, Lane JA, et al. ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15): 1415–1424.
    CrossRefPubMed
  75. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015; 33(3): 272–277.
    CrossRefPubMed
  76. Serrano NA, Anscher MS. Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations. Oncology. 2016; 30(3): 229–236.
    CrossRef
  77. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17(8): 1047–1060.
    CrossRefPubMed
  78. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016; 17(8): 1061–1069.
    CrossRefPubMed
  79. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3): 289–295.
    CrossRefPubMed
  80. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015; 33(4): 332–339.
    CrossRefPubMed
  81. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020; 5(4): 659–665.
    CrossRefPubMed
  82. Care of Prostate Cancer Patients During the COVID-19 Pandemic: Recommendations of the NCCN . https://www.nccn.org/covid-19/pdf/NCCN_PCa_COVID_guidelines.pdf.
  83. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020; 5(4): 659–665.
    CrossRefPubMed
  84. Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196): 385–395.
    CrossRefPubMed
  85. Zaorsky NG, Ohri N, Showalter TN, et al. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev. 2013; 39(7): 728–736.
    CrossRefPubMed
  86. Koontz BF, Bossi A, Cozzarini C, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015; 68(4): 683–691.
    CrossRefPubMed
  87. Yong JHe, Mainprize JG, Yaffe MJ, et al. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen. 2021; 28(2): 100–107.
    CrossRefPubMed
  88. Yin K, Singh P, Drohan B, et al. Breast imaging, breast surgery, and cancer genetics in the age of COVID-19. Cancer. 2020; 126(20): 4466–4472.
    CrossRefPubMed
  89. Miller MJ, Xu L, Qin J, et al. Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(4): 109–113.
    CrossRefPubMed
  90. ASCO. COVID-19 Vaccine and patients with cancer. https://www.asco.org/covid-resources/vaccines-patients-cancer.
  91. NCCN: Cancer and COVID-19 Vaccination Version 1.0 1/22/2021. www.nccn.org/covid-19/pdf/COVID-19_Vaccination.
  92. Lee L, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241): 1919–1926.
    CrossRefPubMed
  93. Rogiers A, Pires da Silva I, Tentori C, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021; 9(1).
    CrossRefPubMed
  94. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335–337.
    CrossRefPubMed
  95. Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020: 1–4.
    CrossRefPubMed
  96. Schwamm LH, Erskine A, Licurse A. A digital embrace to blunt the curve of COVID19 pandemic. NPJ Digit Med. 2020; 3: 64.
    CrossRefPubMed
  97. Canadian Medical Association Virtual Care In Canada: Discussion paper. CMA Health Summit. https://www.cma.ca/sites/default/files/pdf/News/Virtual_Care_discussionpaper_v2EN.pdf (2020-11-13).
  98. Selby P, Popescu R, Lawler M, et al. The Value and Future Developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book. 2019; 39: 332–340.
    CrossRefPubMed
  99. Levine OH, McGillion M, Levine M. Virtual Cancer Care During the COVID-19 Pandemic and Beyond: A Call for Evaluation. JMIR Cancer. 2020; 6(2): e24222.
    CrossRefPubMed
  100. Bitar N, Kattan J, Kourie HR, et al. The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. Future Oncol. 2020; 16(11): 615–617.
    CrossRefPubMed
  101. ESMO. Cancer patient management during the COVID-19 pandemic (2020). www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic.
  102. ESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer (2020). www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era.
  103. Yildiz F, Oksuzoglu B. Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors? Future Oncol. 2020; 16(28): 2191–2195.
    CrossRefPubMed
  104. Tasneem S, Kim A, Bagheri A, et al. Telemedicine Video Visits for patients receiving palliative care: A qualitative study. Am J Hosp Palliat Care. 2019; 36(9): 789–794.
    CrossRefPubMed
  105. Raskin Jo, Lebeer M, De Bondt C, et al. Cancer in the time of COVID-19: expert opinion on how to adapt current practice. Eur Respir J. 2020; 55(5).
    CrossRefPubMed
  106. Cox A, Lucas G, Marcu A, et al. Cancer Survivors' Experience With Telehealth: A Systematic Review and Thematic Synthesis. J Med Internet Res. 2017; 19(1): e11.
    CrossRefPubMed
  107. Larson JL, Rosen AB, Wilson FA. The Effect of Telehealth Interventions on Quality of Life of Cancer Patients: A Systematic Review and Meta-Analysis. Telemed J E Health. 2018; 24(6): 397–405.
    CrossRefPubMed
  108. Hennemann-Krause L, Lopes AJ, Araújo JA, et al. The assessment of telemedicine to support outpatient palliative care in advanced cancer. Palliat Support Care. 2015; 13(4): 1025–1030.
    CrossRefPubMed
  109. Smrke A, Younger E, Wilson R, et al. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020; 6: 1046–1051.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note